Global Dementia Legacy Event: Elisabetta Vaudano DVM PhD

- Innovative Medicines Initiative -

Elisabetta Vaudano

Open collaboration in public-private consortia

(data sharing, dissemination of results)

“Non-competitive” collaborative research for EFPIA pharma companies

Competitive calls to select partners of

EFPIA companies

Key Concepts of IMI

REGULATORS ON BOARD OF

12PROJECTS

50% of projects have REGULATORY AUTHORITIES

representatives in Scientific Advisory Boards

61% of projects reported some form of

PATIENT INVOLVEMENT

Key collaborative activity areas: Diabetes, CNS disorders, Tuberculosis, Patient Reported Outcomes,

Cancer, Preclinical Safety and Education & Training.

IMI signed horizontal agreements with:Critical Path, Juvenile Diabetes Research Foundation as well as

with Clinical Data Interchange Standards Consortium.

Collaboration

€ 1 945 135 308

€ 759,185,796Infectious diseases

€ 214,136,227Drug discovery

€ 182,980,698Brain disorders

€ 116,880,300Metabolic disorders

€ 116,287,312Drug safety

€ 78,225,417Stem cells

€ 72,710786Cancer

IMI funding

Corporate contribution

€ 70,310,746Data management

€ 69,739,527Inflammatory disorders

€ 55,930,958Biologicals

€ 49,310,000Geriatrics

€ 37,966,496Lung diseases

€ 37,378,289Education andtraining

€ 30,601,855Sustainablechemistry

€ 20,426,255Drug delivery

€ 18,118,249Drug kinetics

€ 14,910,397Relative effectiveness

NATURE MEDICINE | NEWS

PartnersAiCuris Johnson&JohnsonAnimal Health MedimmuneDivision of Sanofi Merck Astellas Merck SharpAstraZeneca & Dohme CorpBasilea MerialBoehringer Ingelheim NovartisCubist PfizerGSK RempexJanssen Sanofi

AstraZeneca NovartisBayer PfizerJanssen Sanofi Lundbeck UCBMerck

Abbott Janssen AbbVie LundbeckAC IMMUNE MerckAmgen NovartisAstellas NOVO NORDISKAstraZeneca Orion CorporationBIOGEN IDEC PfizerBoehringer Ingelheim RocheEisai SanofiEli Lilly SERVIERESTEVE UCBGrunenthal ViforGSK

First phase of Europe’s IMI effort: budget breakdown

IMI invests €167 million in 4 projects aiming at:

Developing models to predict the efficacy of drug candidates in patients

Connecting data on 40 millions of individuals to decipher links between genetic background, biological abnormalities, brain imaging changes, mental symptoms and disease progression

Identifying subgroups of the disease allowing to tailor therapies according to the different causal factors involved

Implementing innovative trial designs

How IMI addresses Alzheimer’s disease

January 2014

The Vision for IMI2 – The right prevention and treatment for the right patient at the right time

Biologically heterogeneous

patient population

Graphic adapted from C. Carini, C. Fratazzi, Eur. Pharm. Rev. 2008, 2, 39-45

effective

noteffective

Adverseevents

Trial and Error

effective

noteffective

adverseevents

Dx Test

A

B

Ce.g. biomarker

Information based treatment decisions

vs

The Next Phase: IMI2

IMI2 Key Facts and Strategic Research Agenda

Bigger budget: 3,45 Billion Euro, equally shared by EU and industry

Partnership Not limited to EFPIA members

Dementia and Neurodegeneration have been identified as key research priorities

Thank youwww.imi.europa.eu

@IMI_JU